Advances Toward New Drug Development
In November, we received a series of candidate molecules against our two leading targets. We are now in talks with medicinal chemists to help advance these molecules as well as other tool compounds with already proven results in organoids, to prepare clinical candidates. Through the work of Goldie Lui, a SEngine-sponsored post doc in Chris Kemp's Lab at the Hutch, a recent confirmation of the leading candidate targets has been obtained in ovarian cancer using CRISPR technology. This piece of data together with the organoids results will be crucial for future licensing.